# Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

> **NCT01913067** · PHASE2 · WITHDRAWN · sponsor: **Jules Bordet Institute**

## Conditions studied

- Brain Metastasis
- Breast Cancer
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Cabazitaxel
- **PROCEDURE:** Contrast-enhanced whole brain MRI

## Key facts

- **NCT ID:** NCT01913067
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-09
- **Primary completion:** 2016-05
- **Final completion:** 2016-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Scientific rationale is deemed obsolete. Funders lost interest in the trial.
- **Last updated:** 2014-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01913067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01913067, "Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01913067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*